Time to buy EXEL

[5teamparlay]

Real Time 7.25 1.26 (21.04%) 9:58AM EDT


Sell at 7.60 short term


SOUTH SAN FRANCISCO (TheStreet) -- Treatment with Exelixis'(EXEL) experimental drug cabozantinib helps patients with a form of thyroid cancer significantly extend the time before their disease worsens, according to results from a late-stage study announced Monday.

 

[5teamparlay]

Hopefully on it's way:

1. Real Time7.33

1.34 (22.37%) 10:04AM EDT

 

[5teamparlay]

Keep on trucking:
Real Time7.39 1.40 (23.37%) 10:09AM EDT

 

[5teamparlay]

Bump for higher:




Real Time7.46 1.47 (24.54%) 10:21AM EDT

 

[5teamparlay]

Open:* 7.33
High:* 7.63
Low:* 7.13
*
Volume:* 1,157,312
Avg*Vol:* 1,364,000
Mkt*Cap:* 974.92M

Hit 7.60. Bing bong!!!